Search clinical trials for: Caelyx (pegylated liposomal doxorubicin; SCH 200746)

Total 302 results

Sanofi

Completed

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Neoplasm Malignant

United States
Sutro Biopharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Australia, Korea, Republic of, Israel, Singapore, Canada
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. (MITO29)

Recurrent, Platinum-resistant Ovarian Cancer

Italy
Centocor, Inc.

Completed

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Cancer

United States, Spain
Gynecologic Oncology Group
National Cancer Institute (NCI); Medical Research Council; Southwest Oncology...

Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Metastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the Liver

United States
National Cancer Institute (NCI)

Withdrawn

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
Zhejiang University
Zhejiang Cancer Hospital; First People's Hospital of Hangzhou; Second Affiliated... and other collaborators

Unknown

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients (ESNDBCP)

Breast Cancer

China
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Ovarian Neoplasms

Belgium, France, Slovakia, Spain, Sweden
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Roswell Park Cancer Institute
Ortho Biotech, Inc.

Terminated

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Lymphoma

United States
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy
Beijing Friendship Hospital

Unknown

Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

Hemophagocytic Lymphohistiocytosis

China
Janssen-Ortho Inc., Canada

Completed

A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma
Ludwig Institute for Cancer Research
Johns Hopkins University

Withdrawn

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Solid Tumors | Lymphomas

Germany
AGO Research GmbH

Recruiting

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (MIROVA)

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

Germany
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Sarcoma

United States
Yonsei University

Completed

Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer (REBECA)

Ovarian Cancer

Korea, Republic of
Dr. Susan Love Research Foundation

Unknown

Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

Breast Cancer

United States
Oncotherapeutics

Unknown

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Yonsei University

Not yet recruiting

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (DOVE)

Uterine Cervical Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Vulvar Cancer | Clear Cell Carcinoma | Vagina Neoplasm
Washington University School of Medicine

Completed

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Wenqi Jiang

Unknown

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Fudan University

Recruiting

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Diffuse Large B-cell Lymphoma

China
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO23)

Ovarian Neoplasms

Italy
Nordic Society of Gynaecological Oncology - Clinical...

Completed

Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

Ovarian Cancer | Peritoneal Cancer | Cancer of the Fallopian Tube
Herlev Hospital
Odense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark

Completed

Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer

Breast Cancer

Denmark
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Patients With Ovarian Cancer

Fallopian Tube Cancer | Solid Tumor | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Australia, Bulgaria, Bosnia and Herzegovina, Georgia, Korea, Republic of, Serbia
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

Sarcoma

United States
ImmunoGen, Inc.

Completed

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Belgium, Canada
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Combination With Carboplatin in Ovarian Cancer (SGI-110)

Ovarian Cancer

Canada, United States, United Kingdom
Grupo Español de Investigación en Cáncer de Ovario
GlaxoSmithKline; Hoffmann-La Roche; Apices Soluciones S.L.; AGO Study Group; ARCAGY... and other collaborators

Active, not recruiting

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)

Recurrent Ovarian Carcinoma

France, Spain, Belgium, Italy, Germany
Oncotherapeutics
Celgene Corporation

Unknown

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
The Cleveland Clinic

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Johnson & Johnson Consumer Inc. (J&JCI)

Completed

Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque

Gingivitis | Plaque

United States
Xijing Hospital

Recruiting

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Peking University

Recruiting

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation; Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Multiple Myeloma

United States
University of Kansas Medical Center
Ortho Biotech, Inc.

Completed

A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

Multiple Myeloma
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
ETOP IBCSG Partners Foundation

Terminated

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer (CASA)

Breast Cancer

Italy, Australia, Belgium, Switzerland, Slovenia, Hungary, Sweden, New Zealand, Romania
Jilin University

Unknown

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Antineoplastic Combined Chemotherapy Protocols

China
German Breast Group
Roche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor Pharma

Completed

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Chunyan Sun, MD

Recruiting

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Multiple Myeloma

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
NYU Langone Health
Genentech, Inc.; University of New Mexico Cancer Center

Completed

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Ovarian Cancer

United States
Hope Rugo, MD
Johns Hopkins University; Pfizer; Gilead Sciences; Hoosier Cancer Research Network and other collaborators

Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Unresectable Breast Carcinoma | Stage IIIC Breast Cancer | Triple-Negative Breast Carcinoma | Stage III Breast Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...
GlaxoSmithKline

Recruiting

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33)

Ovarian Cancer

Italy

Search clinical trials for: Caelyx (pegylated liposomal doxorubicin; SCH 200746)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations